



(51) International Patent Classification:

C07D 213/75 (2006.01) **C07D 209/12** (2006.01)
C07D 309/12 (2006.01) **C07D 211/44** (2006.01)
C07D 235/12 (2006.01) **C07D 211/46** (2006.01)
C07D 401/12 (2006.01) **C07D 213/61** (2006.01)
C07D 405/12 (2006.01) **C07D 305/08** (2006.01)
C07D 471/04 (2006.01) **A61K 31/4184** (2006.01)
C07D 271/06 (2006.01)

(21) International Application Number:

PCT/IB2015/052745

(22) International Filing Date:

15 April 2015 (15.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1376/MUM/2014 16 April 2014 (16.04.2014) IN
 2696/MUM/2014 22 August 2014 (22.08.2014) IN
 545/MUM/2015 20 February 2015 (20.02.2015) IN

(71) **Applicant:** GLENMARK PHARMACEUTICALS S.A. [CH/CH]; Chemin de la combeta 5, CH-2300 la chaux-de-fonds (CH).

(72) **Inventors:** CHAUDHARI, Sachin Sundarlal; 15/304, Fam C.h.s., Sector # 11, Koparkhairane, Maharashtra, Navi Mumbai 400709 (IN). THOMAS, Abraham; Flat No. 5, 11th Floor, Building No. A-6 Millennium Towers, Sector 9, Sanpada, Maharashtra, Navi Mumbai 400705 (IN). KADAM, Ashok Bhausaheb; 302, Siddesh Enclave, Plot No. 16, Sector No. 12/A, Koparkhairane, Maharashtra, Navi Mumbai 400709 (IN). DHONE, Sachin Vasantrao; A/P: Makani, Tal: Lohara, Dist: Usmanabad, Maharashtra, Usmanabad 413406 (IN). ADIK, Bharat Gangadhar; A/P: Khanapur, Tal: Shrirampur, Dist: Ahmednagar, Maharashtra, Shrirampur 413739 (IN). KHAIR-ATKAR-JOSHI, Neelima; 101, Devprayag CHS, Bhakti

Mandir Rd, Hari Niwas, Panchpakhadi, Maharashtra, Thane (W) 400602 (IN). SHAH, Daisy Manish; Pad-mashree Bldg, 1st Floor, Flat no 4, Anant Patil Marg, Gokhale Road, Dadar (W), Maharashtra, Mumbai 400028 (IN). BAJPAL, Malini; 47/9 Kabir Marg (Clay Square), Uttar Pradesh, Lucknow 226001 (IN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS



(57) **Abstract:** The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R², R³, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.